Page 6 - Intercure Ltd News Today

Record fiscal year 2022 revenue of $150 million Record fiscal year 2022 Adjusted EBITDA* of $32 million Record fiscal year 2022 net income of $17 million...

Wall Street Thinks INCR Stock Has 165%+ Upside During these trying economic times, few things can warm the cockles of your heart like finding an undervalued stock that is reporting a string of record

23.11.2022 - NEW YORK and TORONTO and HERZLIYA, Israel, Nov. 23, 2022 (GLOBE NEWSWIRE) - InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(InterCure or the Company) is hereby providing an update that further to the announcement from ...

InterCure Announces Record Breaking Third Quarter Financial Results with 63% growth YOY and 6% QoQ growth. Eleventh consecutive quarter of sequential profitable revenue... #INCR #INCRU #InterCure

InterCure is well positioned to take advantage of European cannabis growth. Read why INCR stock is a Buy for global cannabis growth.

The global cannabis market will eventually be bigger than North America, and InterCure is a leading company in global pharmaceutical cannabis. Click to read.

InterCure Ltd (NASDAQ:NASDAQ:INCR) Q2 2022 Earnings Conference Call August 16, 2022, 08:30 ET Company Participants Adam Haliva - Communications Officer Alexander Rabinovitch - CEO &...

Record revenue ofover$37millioniin thesecondquarter of 2022

Record revenue of over $37 millioni in the second quarter of 2022 Representing an annual run rate of $150 million Adjusted EBITDAii for Q2 increased...

In this week’s edition - - DOJ to Address Cannabis “in the days ahead” - Germany Moves Towards Adult-Use Cannabis - Dentons’ Cannabis Group...